LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) Form 8-K — Jun 4, 2026
Lixte Biotechnology Holdings, Inc. (LIXT) closed a registered direct offering on June 4, 2026, raising gross proceeds of approximately $16.6 million. The company issued 2,366,503 shares of common stock and 258,859 pre-funded warrants to purchase common stock at an offering price of $6.31 per share (or $6.30 per pre-funded warrant). The pre-funded warrants are exercisable immediately at a nominal price of $0.0001 per share, effectively allowing investors to acquire shares at a slight discount to the common stock offering price.
Key figures
- Gross Proceeds
- 16600000
- Offering Price
- 6.31
- Shares Offered
- 2366503
- Exercise price
- 0.0001
- Pre funded warrants
- 258859
- Pre funded warrant price
- 6.3
Price after filing
Close on the filing date to close N calendar days later (from $7.00). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.